Thomas Hitchcock, Ph.D.
Thomas Hitchcock, Ph.D. is Chief Innovation Officer at Revance. His relevance to the botulinum toxin industry comes from Revance innovation leadership around the company’s product-science framing for Daxxify and adjacent aesthetics technologies.
His role complements the commercial and ownership context on Revance / Crown Laboratories. It keeps Daxxify’s peptide-formulated identity connected to product science without turning that formulation difference into an unsupported comparison claim.
Role Context
Section titled “Role Context”| Field | Detail |
|---|---|
| Current organization | Revance |
| Current role | Chief Innovation Officer |
| Company context | Revance within the Crown Laboratories corporate group |
| Relevant company | Revance / Crown Laboratories |
| Relevant brand | Daxxify |
| Official leadership source | Revance: Leadership Team and Board of Directors 🔗 |
Career Notes
Section titled “Career Notes”- Revance identifies Hitchcock as Chief Innovation Officer on its current leadership page.
- Revance describes its innovation work across aesthetics, skincare, and therapeutics.
- Revance’s science page describes a peptide-formulated neuromodulator as developed and manufactured by Revance.
- The company’s current portfolio also includes Daxxify safety and indication language for glabellar lines and cervical dystonia in adults.
Innovation and Product-Science Context
Section titled “Innovation and Product-Science Context”Hitchcock is useful because Daxxify is often discussed through its formulation identity. Revance describes Daxxify as a peptide-formulated neuromodulator, and that language helps distinguish the product in the U.S. type A toxin map.
The distinction should remain product-specific. It does not make Daxxify units interchangeable with other botulinum toxin products, and it should not be used as a generalized claim that Daxxify is safer, stronger, longer-lasting, or clinically superior across patients or indications.
Activity and Public Context
Section titled “Activity and Public Context”Revance’s current science materials frame innovation around product development, formulation sciences, R&D, clinical studies, medical affairs, and sponsored-trial support. Hitchcock’s leadership role belongs in that context: he explains the scientific and innovation side of current Revance rather than the historical CEO period around Daxxify’s original approval.
Hitchcock pairs naturally with Darin J. Messina, Ph.D. as an R&D and product-science counterpart outside AbbVie / Allergan Aesthetics.